ADA Updates Oral Cancer Detection Guidelines: Clinical Exams Remain Key
By Dr. Natalie Singh, Health Editor
Published March 2, 2026
The American Dental Association (ADA) has reaffirmed the critical role of comprehensive clinical oral exams in the early detection of oral cancer. Updated guideline recommendations, released in March 2026, emphasize that these exams remain foundational, with cytology adjuncts playing a limited role in informing the need for a biopsy. These are the first living guideline recommendations for early detection of oral squamous cell carcinoma and potentially malignant disorders, updating a 2017 clinical practice guideline.
The Importance of Clinical Exams
The ADA’s updated guidelines stress that clinicians should perform thorough extraoral and intraoral clinical exams on all adult patients. This includes communicating the exam’s role in identifying mucosal abnormalities and obtaining updated medical, social, and dental histories. A punch or scalpel biopsy, followed by histopathological assessment, remains the gold standard for a definitive diagnosis of oral squamous cell carcinoma or oral potentially malignant disorders.
Limited Role for Cytology Adjuncts
The guidelines recommend against using cytology adjuncts – tests involving cell samples collected with a brush – to determine the need for a biopsy or referral in adults with abnormal oral tissues. These tests can produce false positive results, potentially leading to unnecessary procedures. Similarly, they do not recommend using these adjuncts for screening asymptomatic adults without clinically evident abnormalities, as supporting evidence is currently lacking.
However, clinicians may offer a cytology adjunct to adults with clinically worrisome mucosal abnormalities when a biopsy is not feasible, advisable, or indicated. In these limited scenarios, the test should inform – not determine – decisions about biopsy or referral.
Living Guidelines and Continuous Improvement
These recommendations are part of the ADA’s Living Guideline Program, established in 2025. Living guidelines are designed to be updated frequently as modern evidence emerges, providing oral health care providers with more current, evidence-based recommendations. “Because new evidence is evaluated frequently, living guidelines answer critical clinical questions as they emerge,” said Jennifer Holtzman, D.D.S., chair of the ADA Council on Scientific Affairs. [1]
The development of these guidelines involved rigorous methodology, including a living systematic review, and input from an expert multidisciplinary panel led by Mark Lingen, D.D.S., Ph.D., professor of pathology at the University of Chicago Medicine.
What to Do with Negative Cytology Results
A good practice statement included in the guideline emphasizes that a negative cytology result does not rule out disease. If a mucosal abnormality persists or progresses despite a negative result, clinicians should perform a biopsy or refer the patient to a specialist to avoid delayed diagnosis.
Future Recommendations
Future recommendations from the guideline will address vital staining adjuncts, light-based adjuncts, and salivary tests. These are expected to be published later in 2026 in the Journal of the American Dental Association (JADA).
Resources
“Screening and early detection of oral potentially malignant disorders and oral cavity cancer can improve patient outcomes,” said Dr. Lingen. [1]